Tuesday, November 9, 2021
- 8:30AM-10:30AM
-
Abstract Number: 1610
“You Can’t Touch, You Can’t Bond”: COVID-19 and Telehealth Impacts on Communication, Goals, and Experience of Care for Persons with Rheumatoid Arthritis and Their Clinicians
Patient Outcomes, Preferences, & Attitudes Poster IV: COVID-19 (1589–1613)- 8:30AM-10:30AM
-
Abstract Number: 1864
18F-Fluorodeoxyglucose PET/MRI as an Alternative Hybrid Imaging Modality: Comparative Study in a Prospective, Longitudinal Cohort of Patients with Large-Vessel Vasculitis
Vasculitis – Non-ANCA-Associated & Related Disorders Poster II (1862–1888)- 8:30AM-10:30AM
-
Abstract Number: 1707
A Bioengineered Probiotic for the Oral Delivery of an Immunomodulator in Rheumatoid Arthritis
RA – Treatments Poster III: RA Treatments & Their Safety (1674–1710)- 8:30AM-10:30AM
-
Abstract Number: 1639
A Comparison of Cardiovascular Health Indicators in Children with Juvenile Idiopathic Arthritis Who Meet and Do Not Meet the Physical Activity Guidelines
Pediatric Rheumatology – Clinical Poster III: Miscellaneous Rheumatic Disease (1614–1644)- 8:30AM-10:30AM
-
Abstract Number: 1779
A Comparison of Quality of Life Outcomes Between Psoriatic Arthritis and Psoriasis Patients: Data from the Brigham Cohort for Psoriasis and Psoriatic Arthritis Registry (COPPAR)
Spondyloarthritis Including PsA – Diagnosis, Manifestations, & Outcomes Poster IV: Clinical Aspects of PsA & Peripheral SpA (1773–1800)- 8:30AM-10:30AM
-
Abstract Number: 1781
A Direct-to-Patient PsA Screening Survey for Earlier Identification of At-Risk Psoriasis Patients and Reduction of Physician Burden
Spondyloarthritis Including PsA – Diagnosis, Manifestations, & Outcomes Poster IV: Clinical Aspects of PsA & Peripheral SpA (1773–1800)- 8:30AM-10:30AM
-
Abstract Number: 1496
A Metagenome-wide Association Study Revealed Disease-specific Landscape of the Gut Microbiome of Systemic Lupus Erythematosus in Japanese
SLE – Etiology & Pathogenesis Poster (1480–1506)- 8:30AM-10:30AM
-
Abstract Number: 1560
A Multidisciplinary Timely Approach to Initiate Immunosuppressive Biologic Therapy and Improve COVID-19 Cytokine Storm Syndrome Outcome
Infection-related Rheumatic Disease Poster (1530–1564)- 8:30AM-10:30AM
-
Abstract Number: 1486
A Novel Requirement for IFNβ1 Signaling for IFNκ Induction in Keratinocytes
SLE – Etiology & Pathogenesis Poster (1480–1506)- 8:30AM-10:30AM
-
Abstract Number: 1492
A Permissive Factor of Anti-Ro+ Mothers of Neonatal Lupus Children Is Linked to Overt SLE Associated with Immunity to a Gut Commensal
SLE – Etiology & Pathogenesis Poster (1480–1506)- 8:30AM-10:30AM
-
Abstract Number: 1611
A Population-Based Evaluation of Telemedicine Use and Satisfaction in SLE Patients During the COVID-19 Pandemic in Atlanta, Georgia
Patient Outcomes, Preferences, & Attitudes Poster IV: COVID-19 (1589–1613)- 8:30AM-10:30AM
-
Abstract Number: 1726
A Pregnancy Planning Quality Score to Assess a Systematic Intervention to Improve Pregnancy Planning for Women with SLE
Reproductive Issues in Rheumatic Disorders Poster (1711–1731)- 8:30AM-10:30AM
-
Abstract Number: 1876
A Prospective Observational Cohort Study and Systematic Review of 40 Patients with Mouth and Genital Ulcers with Inflamed Cartilage (MAGIC) Syndrome
Vasculitis – Non-ANCA-Associated & Related Disorders Poster II (1862–1888)- 8:30AM-10:30AM
-
Abstract Number: 1721
A Womb with Rheum: Women’s Health Providers’ Confidence and Educational Needs in the Care of Those with Rheumatic Diseases